Comunicati Stampa


Xeptagen HCC biomarker included in a NCI multicenter study

Vanderbilt-Ingram Cancer Center enrols Xeptagen biomarker (SCCA-IgM) in a NCI sponsored multicenter cross-sectional database study to gather information about patients with liver cancer (HCC) over time. Data will be collected on patients diagnosed with hepatocellular carcinoma at Vanderbilt University Medical Center and at other participating hospitals or liver transplantation centers around the nation for inclusion in a national registry of liver cancer patients. A total of 1500 patients will be accrued for the Vanderbilt University Medical Center study and up to 2000 patients for the national study. The study will evaluate etiologic factors associated with HCC in different ethnic groups and in different parts of the United States.